Here are the 10-K annual reports from Aclaris Therapeutics, Inc. (ACRS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ACRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACRS filings page.
Aclaris Therapeutics files its annual report describing a broad immuno-inflammatory pipeline and ongoing operating losses. The company is developing bosakitug and ATI-052 (anti-TSLP–based antibodies) plus oral ITK/JAK3 and ITK inhibitors for atopic dermatitis, asthma and other T cell–mediated diseases, alongside earlier-stage KINect discovery programs.
Aclaris reported net losses of $64.9 million in 2025 and $132.1 million in 2024, with an accumulated deficit of $967.8 million, funded mainly through equity and non-dilutive financing. Cash, cash equivalents and marketable securities totaled $151.4 million as of December 31, 2025, which management believes will fund operations for more than 12 months.